公开(公告)号：WO2009009020A1

公开(公告)日：2009-01-15

申请号：PCT/US2008/008316

申请日：2008-07-07

Applicant: DISCGENICS ,  KUKEKEOV, Valery ,  IGANTOVA, Tatyana ,  DUNTSCH, Christopher

Inventor： KUKEKEOV, Valery ,  IGANTOVA, Tatyana ,  DUNTSCH, Christopher

IPC: C12N5/06

CPC classification number: C12N5/0655 ,  A61K35/12 ,  A61K35/32 ,  C12N2500/25 ,  C12N2500/46 ,  C12N2500/90 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/15 ,  C12N2501/2302 ,  C12N2501/2306 ,  C12N2501/235 ,  C12N2501/392 ,  C12N2533/54 ,  C12N2533/78

Abstract: This invention provides an isolated disc stem cell population, compositions, and methods of obtaining and growing the same. Moreover, this invention provides an isolated discosphere, compositions, and methods of obtaining and growing the same. An artificial disc containing the cells of the present invention is provided together with methods of making the same. This invention also provides a method of treating a subject having a herniated disc utilizing the cells and methods of the invention.

Abstract translation: 本发明提供了一种孤立的椎间盘干细胞群体，组合物及其获得和生长方法。 此外，本发明提供了分离的球状体，组合物以及获得和生长该球状体的方法。 包含本发明的细胞的人造盘与其制备方法一起提供。 本发明还提供了利用本发明的细胞和方法治疗具有突出椎间盘的受试者的方法。

公开(公告)号：WO2008118020A1

公开(公告)日：2008-10-02

申请号：PCT/NL2008/050174

申请日：2008-03-27

Applicant: IPD-THERAPEUTICS B.V. ,  SPANHOLTZ, Jan

Inventor： SPANHOLTZ, Jan

IPC: C12N5/08

CPC classification number: C12N5/0647 ,  C12N5/0646 ,  C12N2500/12 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/21 ,  C12N2501/22 ,  C12N2501/2302 ,  C12N2501/2306 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/235 ,  C12N2501/26 ,  C12N2501/90

Abstract: The invention is related to methods for expanding and differentiating hemopoietic progenitor cells in a medium comprising a collection of cytokines, desulphated glycosaminoglycan and human serum. The invention further relates to a collection of cells obtainable by a method of the invention, use of the collection of cells, and a kit of parts for expanding and differentiating hemopoietic progenitor cells.

Abstract translation: 本发明涉及在包含细胞因子，脱硫的糖胺聚糖和人血清的集合的培养基中扩增和分化造血祖细胞的方法。 本发明还涉及可通过本发明的方法获得的细胞的收集，细胞的收集的使用以及用于扩增和分化造血祖细胞的成套试剂盒。

公开(公告)号：WO2008015682A2

公开(公告)日：2008-02-07

申请号：PCT/IL2007/000970

申请日：2007-08-02

Applicant: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. ,  AMIT, Michal ,  ITSKOVITZ-ELDOR, Joseph

Inventor： AMIT, Michal ,  ITSKOVITZ-ELDOR, Joseph

IPC: C12N5/06

CPC classification number: C12N5/0606 ,  C12N5/0031 ,  C12N5/0037 ,  C12N5/0043 ,  C12N2501/115 ,  C12N2501/15 ,  C12N2501/2306 ,  C12N2501/235 ,  C12N2533/12 ,  C12N2533/90

Abstract: A method of expanding and maintaining human embryonic stem cells (ESCs) in an undifferentiated state by culturing the ESCs in a suspension culture under culturing conditions devoid of substrate adherence is provided. Also provided are a method of deriving ESC lines in the suspension culture and methods of generating lineage-specific cells from ESCs which were expanded in the suspension culture of the present invention.

Abstract translation: 本发明提供了通过在没有底物粘附的培养条件下在悬浮培养物中培养ESC来将人胚胎干细胞（ESC）扩展并保持为未分化状态的方法。 还提供了衍生悬浮培养物中ESC系的方法和从ESCs产生谱系特异性细胞的方法，所述细胞在本发明的悬浮培养物中扩增。

公开(公告)号：WO2005046570A3

公开(公告)日：2006-12-07

申请号：PCT/US2004016790

申请日：2004-05-26

Applicant: UNIV CHICAGO ,  HUBERMAN ELIEZER ,  ZHAO YONG

Inventor： HUBERMAN ELIEZER ,  ZHAO YONG

IPC: A61K35/28 ,  A61K20060101 ,  A61K35/26 ,  A61K48/00 ,  C12N5/00 ,  C12N5/02 ,  C12N5/071 ,  C12N5/074 ,  C12N5/0783 ,  C12N5/0786 ,  C12N5/0793 ,  E02D27/42 ,  G01N33/53

CPC classification number: C12N5/0635 ,  A61K35/12 ,  A61K2035/124 ,  C12N5/0607 ,  C12N5/0619 ,  C12N5/0636 ,  C12N5/0645 ,  C12N5/067 ,  C12N5/069 ,  C12N2501/11 ,  C12N2501/12 ,  C12N2501/13 ,  C12N2501/165 ,  C12N2501/22 ,  C12N2501/2306 ,  C12N2501/235 ,  C12N2501/52 ,  C12N2501/599 ,  C12N2503/02 ,  C12N2506/03 ,  C12N2506/115 ,  G01N33/5073

Abstract: Monocyte derived adult stem cells (MDSCs) isolated from peripheral blood of mammals are provided, along with pharmaceutical compositions containing an MDSC, kits containing a pharmaceutical composition, and methods of preparing, propagating and using MDSCs or differentiated derivatives thereof. The uses of these biological materials include methods of treating disorders or diseases, as well as methods of ameliorating a symptom associated with any such disorder or disease including disorders or diseases associated with platelets.

Abstract translation: 提供从哺乳动物的外周血分离的单核细胞来源的成体干细胞（MDSC），以及含有MDSC的药物组合物，含有药物组合物的试剂盒，以及制备，增殖和使用MDSC或其差异衍生物的方法。 这些生物材料的用途包括治疗疾病或疾病的方法，以及改善与任何此类疾病或疾病相关的症状（包括与血小板相关的疾病或疾病）的方法。

公开(公告)号：WO2005113749A3

公开(公告)日：2006-08-10

申请号：PCT/US2005016552

申请日：2005-05-13

Applicant: BECTON DICKINSON CO ,  XU RUILING ,  DELUCA KEITH ,  LIEBMANN-VINSON ANDREA

Inventor： XU RUILING ,  DELUCA KEITH ,  LIEBMANN-VINSON ANDREA

IPC: A61K35/14 ,  A61K45/00 ,  C12N5/00 ,  C12N5/0775 ,  C12N5/0789

CPC classification number: C12N5/0647 ,  C12N5/0663 ,  C12N2500/25 ,  C12N2500/36 ,  C12N2500/42 ,  C12N2500/90 ,  C12N2501/10 ,  C12N2501/105 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/13 ,  C12N2501/135 ,  C12N2501/14 ,  C12N2501/145 ,  C12N2501/15 ,  C12N2501/155 ,  C12N2501/165 ,  C12N2501/21 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2501/2303 ,  C12N2501/2305 ,  C12N2501/2306 ,  C12N2501/2311 ,  C12N2501/235 ,  C12N2501/26 ,  C12N2501/32 ,  C12N2501/39 ,  C12N2501/415 ,  C12N2501/58 ,  C12N2501/60 ,  C12N2501/70 ,  C12N2501/999 ,  C12N2533/52 ,  C12N2533/54 ,  C12N2533/70

Abstract: The invention provides populations of expanded CD34-expressing cells and methods of use. Particular embodiments provide for defined culture media useful for growing these cells, and grafts comprising these cells. The invention finds use in methods for reconstituting, repairing, and regenerating tissue damage.

Abstract translation: 本发明提供了扩增的CD34表达细胞和使用方法的群体。 具体实施方案提供用于生长这些细胞的限定的培养基和包含这些细胞的移植物。 本发明用于重组，修复和再生组织损伤的方法。

公开(公告)号：WO2005045010A1

公开(公告)日：2005-05-19

申请号：PCT/KR2004/002715

申请日：2004-10-25

Applicant: HISTOSTEM CORPORATION ,  KIM, Sung-Whan ,  HAN, Hoon

Inventor： KIM, Sung-Whan ,  HAN, Hoon

IPC: C12N5/08

CPC classification number: C12N5/0665 ,  C12N2501/125 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2306

Abstract: The present invention relates to a method of isolating and culturing mesenchymal stem cells using umbilical cord blood that is most ideal for cell therapy. The method comprises adding an anti-coagulant to umbilical cord blood having a volume of more than 45 ml per unit, which is obtained within 24 hours after parturition; diluting the resulting mixture of the anti-coagulant and umbilical cord blood with an αMEM (alpha-minimum essential medium), followed by centrifugation to harvest monocytes; and subjecting the obtained monocytes into suspension culture in the αMEM containing Stem Cell Factor, GM-CSF (granulocyte-macrophage colony-stimulating factor), G-CSF (granulocyte colony-stimulating factor), IL-3 (interleukin-3) and IL-6 (interleukin-6).

Abstract translation: 本发明涉及一种使用脐带血分离和培养间充质干细胞的方法，其是细胞治疗最理想的方法。 该方法包括向分娩后24小时内获得的每单位体积超过45ml的脐带血添加抗凝血剂; 用αMEM（α-minimum必需培养基）稀释所得的抗凝血剂和脐带血混合物，然后离心收获单核细胞; 并将所获得的单核细胞在含有干细胞因子，GM-CSF（粒细胞 - 巨噬细胞集落刺激因子），G-CSF（粒细胞集落刺激因子），IL-3（白细胞介素-3）和IL -6（白介素-6）。

公开(公告)号：WO2005007799A3

公开(公告)日：2005-03-03

申请号：PCT/IL2004000643

申请日：2004-07-15

Applicant: GAMIDA CELL LTD ,  HASSON ARIK ,  GRYNSPAN FRIDA

Inventor： HASSON ARIK ,  GRYNSPAN FRIDA

IPC: C12N20060101 ,  C12N5/00 ,  C12N5/02 ,  C12N5/074 ,  C12N5/0775 ,  C12N5/0789

CPC classification number: C12N5/0647 ,  C12N5/0663 ,  C12N5/0692 ,  C12N2500/20 ,  C12N2500/44 ,  C12N2501/11 ,  C12N2501/113 ,  C12N2501/115 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/155 ,  C12N2501/2306 ,  C12N2501/235 ,  C12N2501/237 ,  C12N2501/26 ,  C12N2501/39

Abstract: Methods of ex-vivo expansion of fetal and/or adult progenitor, and umbilical cord blood, bone marrow or peripheral blood derived stem cells in bioreactors for bone marrow transplantation, transfusion medicine, regenerative medicine and gene therapy.

Abstract translation: 用于骨髓移植，输血医学，再生医学和基因治疗的生物反应器中胎儿和/或成体祖细胞，脐带血，骨髓或外周血源性干细胞的离体扩增方法。

公开(公告)号：WO0070022A2

公开(公告)日：2000-11-23

申请号：PCT/US0012895

申请日：2000-05-12

Applicant: HOPE CITY

Inventor： SHIH CHU-CHIH

IPC: A61K35/12 ,  C07K14/47 ,  C12N5/0789 ,  C12N5/00

CPC classification number: C12N5/0647 ,  A61K2035/124 ,  C07K14/4718 ,  C12N2501/125 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/2306 ,  C12N2501/235 ,  C12N2502/1394

Abstract: A method for the ex-vivo expansion of mammalian hematopoietic stem cells (HSC) comprises culturing isolated HSC in a culture system comprising a culture medium in the presence of a stem cell expansion promoting factor (SCEPF) which may be obtained by culturing murine stromal cells in the presence of an amount of leukemia inhibitory factor (LIF) sufficient to stimulate the production and secretion of said expansion promoting factor.

Abstract translation: 哺乳动物造血干细胞（HSC）的离体扩增方法包括在干细胞扩增促进因子（SCEPF）存在下，在包含培养基的培养系统中培养分离的HSC，其可以 通过在足以刺激所述扩张促进因子的产生和分泌的量的白血病抑制因子（LIF）的存在下培养鼠基质细胞获得。

公开(公告)号：WO1997047734A1

公开(公告)日：1997-12-18

申请号：PCT/US1997010316

申请日：1997-06-13

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  PEDERSEN, Roger, A.

IPC: C12N05/06

CPC classification number: C12N5/0606 ,  C12N2500/90 ,  C12N2501/2306 ,  C12N2501/235 ,  C12N2501/237 ,  C12N2501/33 ,  C12N2502/13 ,  C12N2503/02

Abstract: Methods are provided for deriving and propagating passagable pluripotent stem cells from early primate embryos. The passagable pluripotent stem cells are capable of differentiating into a variety of intermediate stem cell types through modified in vitro culture conditions, and as such are useful as a model for early development, and for treatment of a variety of genetic and degenerative diseases and for assay compounds to determine their effect on development.

Abstract translation: 提供用于从早期灵长类动物胚胎衍生和繁殖可传播的多能干细胞的方法。 可传染的多能干细胞能够通过体外修饰培养条件将其分化成多种中等干细胞类型，因此可用作早期发育的模型，以及用于治疗各种遗传和退行性疾病和用于测定 化合物，以确定其对发育的影响。

公开(公告)号：WO9716535A3

公开(公告)日：1997-08-28

申请号：PCT/EP9604698

申请日：1996-10-29

Applicant: SANDOZ LTD ,  SYSTEMIX INC ,  SANDOZ AG

Inventor： MURRAY LESLEY J ,  YOUNG JUDY C

IPC: C12N15/09 ,  A61K31/00 ,  A61K35/12 ,  A61K38/00 ,  A61K38/22 ,  A61K48/00 ,  A61P7/00 ,  C07K14/52 ,  C12N5/0775 ,  C12N5/0789 ,  C12N5/10 ,  C12Q1/68 ,  C12N5/08 ,  A61K35/28 ,  C12N15/63

CPC classification number: C12N5/0647 ,  A61K38/00 ,  A61K48/00 ,  A61K2035/124 ,  C07K14/52 ,  C12N5/0669 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/2306 ,  C12N2501/235 ,  C12N2502/1394

Abstract: Myeloproliferative leukemia receptor (mpl) ligands, such as thrombopoietin, act on a primitive subpopulation of human stem cells having the characteristics of self-renewal and ability to give rise to all hematopoietic cell lineages. Thrombopoietin supports both megakaryocytic differentiation and primitive progenitor cell expansion of CD34 + and CD34 + sub-populations (CD34 + Lin - , CD34 + Thy-1 + Lin - , and CD34 + Lin - Rh123 lo ). Thrombopoietin also stimulated quiescent human stem cells to begin cycling. Thus, mpl ligands are useful for expanding primitive stem cells for restoration of hematopoietic capabilities and for providing modified human stem cells for gene therapy applications.